Related Experiment Videos
Corticosteroids can reverse severe imatinib-induced hepatotoxicity
Dario Ferrero1, Enrico Maria Pogliani, Giovanna Rege-Cambrin
1Divisione di Ematologia dell'Università degli Studi di Torino, Molinette Hospital, Turin, Italy. daferrero@yahoo.com
Haematologica
|June 21, 2006
Summary
Corticosteroids can effectively manage severe imatinib-induced liver toxicity in chronic myeloid leukemia (CML) patients. This treatment allows patients to continue imatinib therapy, avoiding permanent discontinuation due to hepatotoxicity.
Area of Science:
- Hematology
- Hepatology
- Pharmacology
Background:
- Imatinib is a crucial therapy for chronic myeloid leukemia (CML).
- Severe hepatotoxicity occurs in 1-5% of CML patients on imatinib, often necessitating treatment cessation.
- Alternative therapies may be less effective than imatinib.
Purpose of the Study:
- To investigate the efficacy of corticosteroids in managing imatinib-induced hepatotoxicity.
- To determine if corticosteroid treatment allows for the resumption of imatinib therapy.
Main Methods:
- Case series of 5 CML patients experiencing grade 3-4 hepatotoxicity.
- Exclusion of other causes of liver damage.
- Treatment with prednisone or methylprednisolone (25-40 mg/day).
- Monitoring for resolution of hepatotoxicity and ability to resume imatinib.
Main Results:
- Hepatotoxicity resolved in all 5 patients within 3-8 weeks of corticosteroid treatment.
- Two patients experienced recurrence upon attempting low-dose imatinib.
- All patients successfully resumed full-dose imatinib after corticosteroid therapy.
- Corticosteroids were tapered over 3-5 months without recurrence.
Conclusions:
- Corticosteroids are effective in resolving imatinib-induced hepatotoxicity.
- This approach can prevent permanent discontinuation of imatinib therapy.
- Corticosteroid treatment facilitates the continued use of the most effective anti-CML therapy.